Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Trial of Karenitecin (BNP1350) in Patients With Malignant Melanoma

NCT00062491 is registered in ClinicalTrials.gov with BioNumerik Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00062491
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00062491 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Trial of Karenitecin (BNP1350) in Patients With Malignant Melanoma
Lead sponsor
BioNumerik Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2002
Completion date
November 30, 2005
Enrollment
46 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma, neoplasm